Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Incyte Corp announces positive results from phase iii study of ruxolitinib in patients with polycythemia vera


Friday, 7 Mar 2014 02:00am EST 

Incyte Corp:Says that pivotal Phase III trial of ruxolitinib has met its primary endpoint.Achieving phlebotomy independence and reducing spleen size by 35 percent or more.Says the safety profile of ruxolitinib was generally consistent with previous studies based on initial review of the data.Ruxolitinib is approved to treat Patients in the United States. 

Company Quote

107.69
-0.72 -0.66%
22 May 2015